| D008297 |
Male |
|
Males |
|
| D011018 |
Pneumonia, Pneumococcal |
A febrile disease caused by STREPTOCOCCUS PNEUMONIAE. |
Pneumococcal Pneumonia,Pneumococcal Pneumonias,Pneumonias, Pneumococcal |
|
| D003362 |
Cost-Benefit Analysis |
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. |
Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses |
|
| D005260 |
Female |
|
Females |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D001428 |
Bacterial Vaccines |
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. |
Bacterial Vaccine,Bacterin,Vaccine, Bacterial,Vaccines, Bacterial |
|
| D013296 |
Streptococcus pneumoniae |
A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. |
Diplococcus pneumoniae,Pneumococcus |
|
| D014611 |
Vaccination |
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. |
Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations |
|